Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Common diabetes drug may limit your workout — study tests the theory

NCT ID NCT06638671

Knowledge-focused Sponsor: University of Virginia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether short-term use of metformin, a common diabetes drug, changes how well healthy young adults can exercise. Fourteen participants took metformin or a placebo and did bike tests to measure endurance and blood lactate levels. The goal was to see if metformin reduces exercise capacity, as some earlier research suggested.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metformin
What this could lead to
If it works, this could help doctors understand how metformin affects exercise performance, which may guide advice for people taking the drug.
What could go wrong
This is a small, early-phase study with only 14 healthy young adults, so results may not apply to older or less active people. The findings are about exercise capacity, not disease treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

14 people

The number who actually took part.

Started

Jan 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 30 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 18-30 years old * Metformin-naïve * BMI \< 30 kg/m2 * Recreationally active (≥ 3 days/week of exercise) * Females must be premenopausal and report normal menstrual cycles * Willingness and ability to comply with scheduled visits and study procedures. Exclusion Criteria: * History of cardiometabolic disease, such as type 1 or type 2 diabetes * Smoking (must have quit at least 6 mos prior) * Use of medication that significantly alters glucose regulation (e.g., metformin, insulin, GLP-1 receptor agonists, SGLT-2 inhibitors, biguanides) * Severe liver or kidney disease, or medications to treat liver or kidney disease * Pregnant, breastfeeding, or plans to become pregnant during study period

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Exercise capacity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Exercise capacity Metformin

Contacts and locations

Locations

  • University of Virginia

    Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.